Johnson & Johnson has received European Commission approval for nipocalimab, marketed as IMAAVY, as an add-on therapy for ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted ...

From stroke and brain injury, to cognitive impairment and neurological diseases, various conditions can have a profound ...

State Medicaid agencies are struggling to pay for an intensive therapy for children with autism — and looming federal cuts ...

Johnson & Johnson JNJ announced that the European Commission has approved Imaavy (nipocalimab) as an add-on therapy for the ...

The U.S. Food and Drug Administration (FDA) has granted traditional approval to Jaypirca (pirobrutinib) for the treatment of ...

The world might look a little different than it did in the early 2000s — OK, a lot different — but the music that defined a ...

Beerse: Johnson & Johnson has announced that the European Commission has approved a Marketing Authorisation for IMAAVY ...

For many today, mental health isn’t just private—it’s public, performative, and yes, profitable. Social media platforms like ...

Premenopausal women and men with endocrine- or medication-related risks for osteoporosis may be affected, and timely bone densitometry assessment helps prevent delays in diagnosis.

Treatment with once-daily brepocitinib improved skin disease, muscle and physical function measures for adults with ...

A suite of products promise smoother skin, bigger muscles and longer life. But what are peptides? And do they work?